about
Procarbazine, lomustine and vincristine for recurrent high-grade gliomaHeat shock protein vaccines against glioblastoma: from bench to bedsideCombination of bevacizumab, irinotecan, and temozolomide for refractory or relapsed neuroblastoma: Results of a phase II study.Single vs. combination immunotherapeutic strategies for glioma.N-(2-hydroxyphenyl)acetamide (NA-2) and Temozolomide synergistically induce apoptosis in human glioblastoma cell line U87.Silencing erythropoietin receptor on glioma cells reinforces efficacy of temozolomide and X-rays through senescence and mitotic catastropheEGFRvIII/integrin β3 interaction in hypoxic and vitronectinenriching microenvironment promote GBM progression and metastasis.Bevacizumab treatment for newly diagnosed glioblastoma: Systematic review and meta-analysis of clinical trials.Clinical aggressiveness of malignant gliomas is linked to augmented metabolism of amino acids.Procarbazine, lomustine and vincristine for recurrent high-grade glioma.CD133 in brain tumor: the prognostic factor.Role of HCP5-miR-139-RUNX1 Feedback Loop in Regulating Malignant Behavior of Glioma CellsPrognostic factors in recurrent glioblastoma patients treated with bevacizumab.Triazole RGD antagonist reverts TGFβ1-induced endothelial-to-mesenchymal transition in endothelial precursor cells.The Long and Winding Road: From the High-Affinity Choline Uptake Site to Clinical Trials for Malignant Brain Tumors.Expression of CDC5L is associated with tumor progression in gliomas.Management and treatment recommendations for World Health Organization Grade III and IV gliomas.The Prognostic Significance of Combining VEGFA, FLT1 and KDR mRNA Expressions in Brain Tumors.Fighting vessel dysmorphia to improve glioma chemotherapy.Evolutionary basis of a new gene- and immune-therapeutic approach for the treatment of malignant brain tumors: from mice to clinical trials for glioma patients.Treatment of Glioblastoma in Older Adults.Bevacizumab in temozolomide refractory high-grade gliomas: single-centre experience and review of the literature.Development of Molecularly Targeted Agents and Immunotherapies in Glioblastoma: A Personalized Approach.CNS cancer immunity cycle and strategies to target this for glioblastoma.Identification of transcriptome signature for predicting clinical response to bevacizumab in recurrent glioblastoma.BPLLDA: Predicting lncRNA-Disease Associations Based on Simple Paths With Limited Lengths in a Heterogeneous Network
P2860
Q24187436-B5859E83-8799-46C0-B725-C97F597EBBFCQ28087775-0B2845CB-534D-4B83-8044-8A39B2EF8F59Q33438641-8074B996-E736-4634-A885-A25E0773B3F3Q33746041-76F2C477-451E-4FB6-BDA2-65EA04A37F14Q35056313-9BF59247-1F16-4A1B-B0A0-577D3E1D8E01Q35273402-D7EA6759-87E4-417F-90A6-E8FE70D9DB6CQ36782548-47BA11F0-A1C5-4C18-8BA9-459B04827869Q36824472-3A5A4ABF-5930-487B-BB8B-ACBBEA5A64D6Q37730054-C8393F2D-1A1F-4899-9EFB-7A49AD82EF3AQ38660976-10D2F13B-894B-490C-B59F-98781AC34E12Q38722833-1D155B1A-763F-4FC5-A35E-E0B7A7E37997Q38756966-97479562-2272-4787-BCD9-B41837200DF5Q39755619-D4F9E50F-772A-4DB8-8E69-99D91B904EA9Q40926459-CBF76A5D-4A69-4676-8945-5BEF7446D143Q41189810-374FAA5A-5B42-4ACE-8F3F-5DF1FADEBB7AQ41194997-2EF9E7AB-D4DF-468D-985D-A7544C4F4308Q41706326-17F340E0-3E37-453F-B177-0945A563AD46Q42434379-859575BF-4EE6-404A-A87A-E008EF48BF11Q47129095-B7F99125-95D9-4A78-B0B3-464D3611E16EQ47318878-E11EC069-2E11-4A83-9E30-6D05C59573A9Q47998543-1E81DD56-0CC3-449F-B434-E6D08B223409Q49635346-4EB28CCA-AA86-4907-83A3-C7565A9913C8Q52365121-745CB186-5C33-4F17-855B-3FEF8F82E177Q55259532-4DA7D962-EA70-4448-B54D-914B67139F3DQ55312333-44206CCE-703A-42B2-973C-D7C30C51FA50Q59136386-5F09CDAE-DD52-498F-940A-B780F5FD88E0
P2860
description
2014 nî lūn-bûn
@nan
2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Antiangiogenic therapy for high-grade glioma
@ast
Antiangiogenic therapy for high-grade glioma
@en
Antiangiogenic therapy for high-grade glioma
@en-gb
Antiangiogenic therapy for high-grade glioma
@nl
type
label
Antiangiogenic therapy for high-grade glioma
@ast
Antiangiogenic therapy for high-grade glioma
@en
Antiangiogenic therapy for high-grade glioma
@en-gb
Antiangiogenic therapy for high-grade glioma
@nl
prefLabel
Antiangiogenic therapy for high-grade glioma
@ast
Antiangiogenic therapy for high-grade glioma
@en
Antiangiogenic therapy for high-grade glioma
@en-gb
Antiangiogenic therapy for high-grade glioma
@nl
P2093
P2860
P31
P1476
Antiangiogenic therapy for high-grade glioma
@en
P2093
Helen Wheeler
Malaka S Ameratunga
Nick Pavlakis
Robin Grant
P2860
P356
10.1002/14651858.CD008218.PUB3
P577
2014-09-22T00:00:00Z